In addition, differences in AKT activity observed in different ovarian cancer cell lines contribute to the cell-specific sensitivity to pharmacological treatment by rapamycin and, more in general, by mTOR inhibitors[16]. This evidence concerns the gene MTOR and ovarian carcinoma.